AI-Enabled Reanalysis Confirms Strong Efficacy of ARG-007 in Severe Stroke Patients.
Argenica Therapeutics (ASX: AGN) has delivered transformational results from an advanced AI-driven reanalysis of its Phase 2 stroke trial, confirming that ARG-007 provides statistically significant clinical benefits for severe acute ischaemic stroke patients. Using the FDA-approved Brainomix 360 AI tool, the reanalysis standardised stroke severity scoring and revealed improved functional outcomes at 24 hours and 90 days, alongside substantially reduced infarct volumes—clear indicators of potent neuroprotection.
ARG-007 showed the strongest benefit in patients with larger infarct cores and poor collaterals, representing the highest-need population with limited treatment options. With these reinforced findings, Argenica is progressing towards a precision medicine-focused Phase 2b trial, targeting patients most likely to benefit. This marks a major step forward in developing the first adjunctive neuroprotective therapy for severe stroke.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au
x
Daily Dose of Buy, Sell & Hold recommendations before the market opens.
Start Your 7 Days Free Trial Now!
We use cookies to help us improve, promote, and protect our services. By continuing to use this site, we assume you consent to this. Read our Privacy Policy and Terms & Conditions
AI-Enabled Reanalysis Confirms Strong Efficacy of ARG-007 in Severe Stroke Patients.
Argenica Therapeutics (ASX: AGN) has delivered transformational results from an advanced AI-driven reanalysis of its Phase 2 stroke trial, confirming that ARG-007 provides statistically significant clinical benefits for severe acute ischaemic stroke patients. Using the FDA-approved Brainomix 360 AI tool, the reanalysis standardised stroke severity scoring and revealed improved functional outcomes at 24 hours and 90 days, alongside substantially reduced infarct volumes—clear indicators of potent neuroprotection.
ARG-007 showed the strongest benefit in patients with larger infarct cores and poor collaterals, representing the highest-need population with limited treatment options. With these reinforced findings, Argenica is progressing towards a precision medicine-focused Phase 2b trial, targeting patients most likely to benefit. This marks a major step forward in developing the first adjunctive neuroprotective therapy for severe stroke.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au